Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir plus chloroquine phosphate for COVID-19
ChiCTR2000030987Phase 3Recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of favipiravir and chloroquine in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Beijing Chaoyang Hospital. Primary endpoints: Improvement or recovery of respiratory symptoms and Time to viral nucleic acid conversion from positive to negative in throat swab or sputum. Started Mar 2020; status: recruiting.
02
Drugs
favipiravirchloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030987.